Raymond James Financial Services Advisors, Inc. - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q1 2023$37,118
-27.2%
11,248
-1.7%
0.00%
Q3 2022$51,000
+59.4%
11,448
-2.6%
0.00%
Q2 2022$32,000
-20.0%
11,748
-2.4%
0.00%
Q1 2022$40,000
-16.7%
12,0310.0%0.00%
Q4 2021$48,000
+14.3%
12,031
-5.5%
0.00%
Q3 2021$42,000
-14.3%
12,731
-1.9%
0.00%
Q2 2021$49,000
-3.9%
12,981
-2.0%
0.00%
Q1 2021$51,000
-5.6%
13,240
+11.6%
0.00%
Q4 2020$54,00011,8690.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders